Last updated: April 10, 2024
Sponsor: Perceive Biotherapeutics, Inc.
Overall Status: Active - Not Recruiting
Phase
1/2
Condition
Geographic Atrophy
Macular Degeneration
Aging
Treatment
VOY-101
Clinical Study ID
NCT05380492
PBI-AMD-001
Ages > 50 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Are ≥50 years of age at the time of consent.
- Are willing and able to understand and provide written informed consent.
- Are willing and able to return for scheduled treatment and follow-up examinations.
- Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
- Well-demarcated GA secondary to AMD in the absence of MNV and in the absence ofhistory of MNV.
- Absence of signs of non-exudative MNV.
- Additional Ocular Inclusion Criteria
- Meet certain genotype criteria for risk of AMD.
Exclusion
Exclusion Criteria:
- Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use anddocument use of effective contraception for the duration of the study.
- Additional Systemic, Ocular, and Genetic Exclusion Criteria.
Study Design
Total Participants: 45
Treatment Group(s): 1
Primary Treatment: VOY-101
Phase: 1/2
Study Start date:
November 17, 2022
Estimated Completion Date:
November 30, 2025
Study Description
Connect with a study center
Ophthalmic Consultants of Boston
Boston, Massachusetts 02114
United StatesSite Not Available
Retina Consultants of Texas
Bellaire, Texas 77401
United StatesSite Not Available
University of Utah
Salt Lake City, Utah 84112
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.